Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Seladelpar in PBC with Inadequate Response/Intolerance to UDCA
NCT03602560Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of seladelpar in primary biliary cholangitis (PBC) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at 3 months. Started Oct 2018; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03602560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602560.